DK2255184T3 - Serotonintransportergen og behandling af alkoholisme - Google Patents

Serotonintransportergen og behandling af alkoholisme

Info

Publication number
DK2255184T3
DK2255184T3 DK09714591.6T DK09714591T DK2255184T3 DK 2255184 T3 DK2255184 T3 DK 2255184T3 DK 09714591 T DK09714591 T DK 09714591T DK 2255184 T3 DK2255184 T3 DK 2255184T3
Authority
DK
Denmark
Prior art keywords
alcoholism
treatment
transporter gene
serotonin transporter
serotonin
Prior art date
Application number
DK09714591.6T
Other languages
English (en)
Inventor
Bankole A Johnson
Original Assignee
Univ Virginia Patent Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Found filed Critical Univ Virginia Patent Found
Application granted granted Critical
Publication of DK2255184T3 publication Critical patent/DK2255184T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/307—Drug dependency, e.g. alcoholism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
DK09714591.6T 2008-02-28 2009-02-27 Serotonintransportergen og behandling af alkoholisme DK2255184T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3226308P 2008-02-28 2008-02-28
US5930108P 2008-06-06 2008-06-06
US14644009P 2009-01-22 2009-01-22
PCT/US2009/035420 WO2009108837A2 (en) 2008-02-28 2009-02-27 Serotonin transporter gene and treatment of alcoholism

Publications (1)

Publication Number Publication Date
DK2255184T3 true DK2255184T3 (da) 2013-07-22

Family

ID=41016720

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09714591.6T DK2255184T3 (da) 2008-02-28 2009-02-27 Serotonintransportergen og behandling af alkoholisme

Country Status (19)

Country Link
US (10) US8697361B2 (da)
EP (1) EP2255184B1 (da)
JP (1) JP2011515076A (da)
KR (1) KR20100127799A (da)
CN (1) CN102016571A (da)
AU (1) AU2009219174B2 (da)
BR (1) BRPI0908425B8 (da)
CA (1) CA2716498C (da)
DK (1) DK2255184T3 (da)
EA (1) EA019200B1 (da)
ES (1) ES2430940T3 (da)
HK (1) HK1151091A1 (da)
HR (1) HRP20130621T1 (da)
IL (1) IL207822A (da)
MX (1) MX2010009509A (da)
NZ (1) NZ588037A (da)
PL (1) PL2255184T3 (da)
WO (1) WO2009108837A2 (da)
ZA (1) ZA201006485B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8631151B2 (en) 2006-05-18 2014-01-14 Intel Corporation Techniques for guaranteeing bandwidth with aggregate traffic
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
CA2677205A1 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
CA2716498C (en) 2008-02-28 2020-12-22 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
EP2425013A1 (en) * 2009-05-01 2012-03-07 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
LT2801625T (lt) 2010-07-02 2018-03-12 University Of Virginia Patent Foundation Molekulinis genetinis būdas, skirtas priklausomybės nuo alkoholio ir narkotikų gydymui ir diagnozavimui
JP5899527B2 (ja) * 2011-03-14 2016-04-06 国立研究開発法人理化学研究所 第６染色体短腕２１．３３領域の一塩基多型に基づく抗てんかん薬による薬疹リスクの検査方法
WO2012158897A1 (en) 2011-05-17 2012-11-22 National Ict Australia Limited Computer-implemented method and system for detecting interacting dna loci
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP2015165780A (ja) * 2014-03-04 2015-09-24 大学共同利用機関法人情報・システム研究機構 視床−皮質軸索でｅｇｆｐを発現するマウス
ES2546896B1 (es) * 2014-03-26 2016-07-07 Universitat De Les Illes Balears Método para la predicción y/o la prevención de sobrepeso, obesidad y/o sus complicaciones mediante análisis de expresión génica
CN104615913B (zh) * 2014-12-31 2017-11-07 深圳先进技术研究院 一种标志物相关性检测方法以及装置
EP3273952B1 (en) 2015-03-26 2022-06-15 Sen-Jam Pharmaceutical LLC Combination of naproxen and fexofenadine to inhibit symptoms associated with veisalgia
RU2695659C1 (ru) * 2018-09-28 2019-07-25 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ прогнозирования оценки эффективности терапии промазином для лечения расстройств, сопровождающихся развитием психотической симптоматики
KR101950372B1 (ko) * 2018-10-30 2019-02-20 한국화학연구원 스테로이드 대사 변화 분석 방법, 이에 따른 인터넷 또는 스마트폰 중독 예측방법 및 이를 실현하기 위한 프로그램이 저장된 컴퓨터 판독 가능한 기록 매체
RU2700565C1 (ru) * 2019-06-06 2019-09-19 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью Способ определения предрасположенности к развитию ожирения у детей в условиях избыточной контаминации алюминием
US20210043293A1 (en) * 2019-08-05 2021-02-11 RxAssurance Corporation (d/b/a OpiSafe) Techniques for providing interactive clinical decision support for drug dosage reduction
KR102203807B1 (ko) * 2019-08-05 2021-01-15 한국과학기술연구원 중독의 진단용 조성물, 키트 및 이를 이용한 중독의 진단을 위한 세로토닌의 검출 방법
RU2722834C1 (ru) * 2019-12-19 2020-06-04 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ прогнозирования оценки эффективности терапии флувоксамином для лечения расстройств, сопровождающихся развитием депрессивной симптоматики
WO2021127391A1 (en) * 2019-12-20 2021-06-24 The Jackson Laboratory Molecular targets for addiction
CN112002375B (zh) * 2020-07-30 2022-10-14 苏州因顿医学检验实验室有限公司 一种酒量预测模型的构建方法
US20220117916A1 (en) * 2020-10-19 2022-04-21 SafeRx Pharmaceuticals, LLC Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose
RU2753899C1 (ru) * 2020-11-23 2021-08-24 Александр Борисович Мулик Способ прогнозирования риска развития алкоголизации населения локальных территорий
WO2022117573A1 (en) * 2020-12-01 2022-06-09 Fundació Institut De Recerca De L'hospital De La Santa Creu I Sant Pau Predicting behavioural addictions
RU2767699C1 (ru) * 2021-09-02 2022-03-18 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ прогнозирования коморбидного течения аффективных расстройств и алкоголизма на основе определения белков сыворотки крови

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA219554A (en) 1922-06-13 Edward A. Taft Knot tying implement
US5550021A (en) 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
RU2075978C1 (ru) 1994-03-21 1997-03-27 Владислав Ефимович Шофер Способ лечения больных хроническим алкоголизмом
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
EP0945133A1 (en) 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US20040167164A1 (en) * 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
AU3997300A (en) 1999-02-22 2000-09-14 Variagenics, Inc. Gene sequence variations with utility in determining the treatment of disease
JP2002537326A (ja) 1999-02-24 2002-11-05 ユニヴァーシティ・オブ・シンシナティ 衝動調節障害の治療のためのスルファメート誘導体の使用
WO2002028275A2 (en) 2000-09-29 2002-04-11 New Health Sciences, Inc. Systems and methods for investigating blood flow
US7122308B2 (en) 2001-02-16 2006-10-17 Centre For Addiction And Mental Health Detection of antidepressant induced mania
US7033771B2 (en) 2001-05-08 2006-04-25 Takeda Pharmaceutical Company Limited Use of insulin response modulators in the treatment of diabetes and insulin resistance
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
HUP0401022A3 (en) 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US20030100479A1 (en) 2001-08-21 2003-05-29 Dow David J. Gene polymorphisms and response to treatment
US20030114475A1 (en) 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
AU2003240253A1 (en) 2002-05-15 2003-12-02 Epidauros Biotechnologie Ag Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
AU2003237657A1 (en) 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
SI2316456T1 (sl) 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7163969B2 (en) 2003-10-14 2007-01-16 Stockhausen, Inc. Superabsorbent polymer aqueous paste and coating
US20050245461A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007009691A2 (en) 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent
WO2007039123A2 (en) 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
DK1928438T3 (da) 2005-09-26 2013-04-22 Avigen Inc Anvendelse af ibudilast til behandling af stofafhængighed
US20070196841A1 (en) 2006-01-20 2007-08-23 Gualberto Ruano Physiogenomic method for predicting response to diet
WO2007095580A2 (en) * 2006-02-15 2007-08-23 The Regents Of The University Of California Treatment response in generalized social phobia
US20070292880A1 (en) 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US7645750B2 (en) 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
MX2009006672A (es) 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
CA2677205A1 (en) 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
US20080228700A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
WO2009010837A2 (en) 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
WO2009026381A2 (en) 2007-08-21 2009-02-26 University Of Virginia Patent Foundation Method, computer program product and system for individual assessment of alcohol sensitivity
CA2697990A1 (en) 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
CA2716498C (en) 2008-02-28 2020-12-22 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US20090269773A1 (en) 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
EP2425013A1 (en) 2009-05-01 2012-03-07 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
LT2801625T (lt) 2010-07-02 2018-03-12 University Of Virginia Patent Foundation Molekulinis genetinis būdas, skirtas priklausomybės nuo alkoholio ir narkotikų gydymui ir diagnozavimui
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
US10997121B1 (en) 2020-07-17 2021-05-04 Snowflake Inc. Attachable-and-detachable database sessions

Also Published As

Publication number Publication date
US20160376658A1 (en) 2016-12-29
US20170226585A1 (en) 2017-08-10
ES2430940T3 (es) 2013-11-22
EP2255184B1 (en) 2013-04-24
US20110112159A1 (en) 2011-05-12
WO2009108837A3 (en) 2009-12-30
HRP20130621T1 (en) 2013-09-30
EP2255184A4 (en) 2011-08-31
IL207822A0 (en) 2010-12-30
BRPI0908425B8 (pt) 2021-05-25
US8697361B2 (en) 2014-04-15
EA201001389A1 (ru) 2011-04-29
US20200199679A1 (en) 2020-06-25
EA019200B1 (ru) 2014-01-30
NZ588037A (en) 2012-08-31
US20190002984A1 (en) 2019-01-03
MX2010009509A (es) 2010-11-30
AU2009219174A1 (en) 2009-09-03
BRPI0908425B1 (pt) 2021-03-09
CN102016571A (zh) 2011-04-13
US20140206734A1 (en) 2014-07-24
HK1151091A1 (en) 2012-01-20
IL207822A (en) 2015-09-24
KR20100127799A (ko) 2010-12-06
JP2011515076A (ja) 2011-05-19
US20190249255A1 (en) 2019-08-15
EP2255184A2 (en) 2010-12-01
PL2255184T3 (pl) 2013-12-31
US20210301346A1 (en) 2021-09-30
CA2716498A1 (en) 2009-09-03
US10995374B2 (en) 2021-05-04
US20160139161A1 (en) 2016-05-19
WO2009108837A2 (en) 2009-09-03
BRPI0908425A2 (pt) 2015-08-04
US10619209B2 (en) 2020-04-14
ZA201006485B (en) 2014-02-26
AU2009219174B2 (en) 2014-04-03
CA2716498C (en) 2020-12-22
US11905562B2 (en) 2024-02-20
US10533226B2 (en) 2020-01-14
US20180251840A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
DK2255184T3 (da) Serotonintransportergen og behandling af alkoholisme
DK2323912T3 (da) Beholderbelysningsindretning og fremgangsmåde til dennes fremstilling
DK1972223T3 (da) Skridsikker trædeflade og fremgangsmåde til fremstilling af en sådan trædeflade
DK2350416T4 (da) Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
DK2480574T3 (da) Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2114447T3 (da) Forebyggelse og behandling af subkliniks pcvd
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2254598T3 (da) Kombination af alfa 7-nikotinagonister og antipsykotika
BRPI0910598A2 (pt) refratário contendo zircônia-carbono e método de produção do mesmo
DK2189537T3 (da) Detektion og behandling af skizofreni
DK2307445T3 (da) Fremgangsmåde til fremstilling af caspofungin og mellemforbindelser heraf
DK2192117T3 (da) Organisk aminsalt af 6-fluor-3-hydroxy-2-pyrazincarbonitril og fremgangsmåde til fremstilling deraf
BRPI0915394A2 (pt) purificação de citoquinas modificadas
DK2274245T3 (da) Fytosystem, dets anvendelse og fremgangsmåde til behandling af spildevand
SMT201600156B (it) Trattamento dell’osteoartrite
DK2501381T3 (da) Behandling af atrieflimmer
DK2406372T3 (da) Prægastrisk esterase og derivater deraf
DK2235021T3 (da) Epoxyguainderivater og behandling af cancer